The oral route remains the most preferred and
patient-friendly mode of drug administration. Microballoons, a non-effervescent
gastroretentive system, are hollow microspheres (<200 µm) composed of
polymers or proteins that exhibit excellent buoyancy due to their internal
cavity. As multiple-unit systems, they ensure uniform drug distribution,
minimise dose dumping, and allow controlled drug release by optimising polymer
composition. Acetohydroxamic acid, a urease inhibitor structurally similar to
urea, effectively inhibits Helicobacter pylori by penetrating bacterial cells
and blocking urease activity, making it suitable for stomach-specific delivery.
This study involved the formulation of acetohydroxamic acid floating
microballoons, the evaluation of gastric retention by X-ray imaging in rabbits,
and bioavailability assessment through pharmacokinetic studies. DSC and FTIR
confirmed drug–polymer compatibility. The percentage yield was in the range of
60-90 % for all the formulations. It was found to be less than 70% yield with
ethyl cellulose and HPMC K4M, and for the optimised formulation, the yield was
around 80 %. The entrapment efficiency was in the range of 60-90 % for all the
formulations and was found to be 89.6%for optimized formulation. The percentage
buoyancywas in the range of 60-90 % for all the formulations and was found to
be 85.5% for optimized formulation. Drug content of all the prepared
formulations was found to be within the acceptable range of 90.0 -110.0%. This
manuscript is important to the scientific community as it provides a
comprehensive and well-validated approach to gastroretentive drug delivery
using floating microballoons as a non-effervescent, multiparticulate system.
The work offers a reproducible formulation strategy for stomach-specific
delivery of urease inhibitors, addressing a critical challenge in the
management of Helicobacter pylori infections. Overall, the findings contribute
valuable translational insights for the development of advanced oral drug
delivery systems with improved clinical efficacy.
Author(s) Details
Munija Pancheddula
Vision College of Pharmaceutical Sciences & Research, Boduppal,
Hyderabad, India.
Nemuri Mounika
Vision College of Pharmaceutical Sciences & Research, Boduppal,
Hyderabad, India.
Upparaboina Srilatha
Vision College of Pharmaceutical Sciences & Research, Boduppal,
Hyderabad, India.
Shayeda
Department of Pharmaceutics, University College of Pharmaceutical Sciences,
Kakatiya University, Warangal-506009, India.
Please see the book here :- https://doi.org/10.9734/bpi/psnid/v10/7065
No comments:
Post a Comment